copayment for ambulatory care in 2004 for individuals with statutory health insurance (SHI). Because persons with private …-in-difference approach to examine whether the new copayment effectively reduced the overall demand for physician visits and to explore … same time, we did not observe a deterrent effect among vulnerable individuals. Thus, the copayment has failed to reduce the …

copayment for ambulatory care in 2004 for individuals with statutory health insurance (SHI). Because persons with private …-in-difference approach to examine whether the new copayment effectively reduced the overall demand for physician visits and to explore … same time, we did not observe a deterrent effect among vulnerable individuals. Thus, the copayment has failed to reduce the …

copayment for ambulatory care in 2004 for individuals with statutory health insurance (SHI). Because persons with private …-in-difference approach to examine whether the new copayment effectively reduced the overall demand for physician visits and to explore … same time, we did not observe a deterrent effect among vulnerable individuals. Thus, the copayment has failed to reduce the …

copayment for ambulatory care in 2004 for individuals with statutory health insurance (SHI). Because persons with private …-in-difference approach to examine whether the new copayment effectively reduced the overall demand for physician visits and to explore … same time, we did not observe a deterrent effect among vulnerable individuals. Thus, the copayment has failed to reduce the …

were introduced in Germany in 1997 to reduce moral hazard and public health expenditures in the market for convalescent …

copayment for ambulatory care in 2004 for individuals with statutory health insurance (SHI). Because persons with private …-in-difference approach to examine whether the new copayment effectively reduced the overall demand for physician visits and to explore … same time, we did not observe a deterrent effect among vulnerable individuals. Thus, the copayment has failed to reduce the …

. Anhand von standardisierten Befragungen untersucht Verena Reichl die Folgen für Ärzte, Patienten und die pharmazeutische und … Ärzten führen die Sparmaßnahmen zu einem veränderten Verordnungsverhalten und bei den Patienten schlagen sie sich in … als wichtigster Partner des Patienten im Rahmen seiner medizinischen Behandlung die Bereitschaft zur Eigenbeteiligung …

drug substitution and competition. Since 2006, Germany follows an innovative approach by differentiating drug co … potential reductions in co-payments. We refer to the latter result as the "co-payment exemption paradox." Our competition proxy …